Analysis of Sexual Bias in Type 2 Innate Lymphoid Cells (ILC2) in Asthmatic Patients

Asthma is more common in males until puberty but becomes more prevalent and more severe in females after puberty suggesting a protective action of male sex hormones. ILC2 have recently emerged as critical players in the initiation of allergic responses. The present team established that androgens, signaling through the nuclear receptor 3 C4 (NR3C4) androgen receptor (AR), negatively control ILC2 at steady state and during lung inflammation. Relevant to this application, females with asthma have more circulating ILC2 than males. The present hypothesis is that harnessing AR signaling in ILC2 may provide a new therapeutic approach to down regulate tissue resident ILC2. This project will analyze the sex bias in circulating ILC2 in female and male patients with moderate to severe asthma. In females with asthma, the team will purify circulating ILC2 from peripheral blood mononuclear cells (PBMC) and expand them in vitro using cytokines and stromal cells in the presence of AR antagonist or agonist ligands. Bulk ILC2 cultures at day 7 will used to measure the expression profile of various gene, including AR.

Inclusion criteria

• Asthma according to the criteria described by Global Initiative for Asthma (GINA) guidelines
• Severe asthma according to the criteria described by the American Thoracic Society (ATS) / European Respiratory Society (ERS) guidelines (for the recruitment of severe patients)
• Mild to moderate asthma based on low or medium dose of inhaled steroids according to GINA guidelines

Exclusion criteria

• Asthma exacerbations defined as oral corticosteroids related to worsening respiratory symptoms within the past 4 weeks
• Pregnant women
• Breastfeeding women
• Autoimmune diseases
• Androgen medication
• Early menopause defined as the absence of menstruation for at least 1 year
• Body mass index ≥ 30 kg/m²
• Weight <40 kg
• Oral corticotherapy for more than 3 months
• Prediction of blood volume collected (care + research)> 80 ml or> 150 ml over a period of 30 days if blood collection within the past 30 days
• known anemia with hemoglobin <10 g/dl